[HTML][HTML] Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an
overall five-year survival rate of less than twenty percent. For patients with unresectable …
overall five-year survival rate of less than twenty percent. For patients with unresectable …
[HTML][HTML] Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
MS Makary, S Ramsell, E Miller, EW Beal… - World Journal of …, 2021 - wjgnet.com
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an
overall five-year survival rate of less than twenty percent. For patients with unresectable …
overall five-year survival rate of less than twenty percent. For patients with unresectable …
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
MS Makary, S Ramsell, E Miller… - World journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an
overall five-year survival rate of less than twenty percent. For patients with unresectable …
overall five-year survival rate of less than twenty percent. For patients with unresectable …
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
MS Makary, S Ramsell, E Miller, EW Beal… - World Journal of …, 2021 - europepmc.org
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an
overall five-year survival rate of less than twenty percent. For patients with unresectable …
overall five-year survival rate of less than twenty percent. For patients with unresectable …
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
MS Makary, S Ramsell, E Miller… - World Journal of …, 2021 - ohiostate.elsevierpure.com
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver and has an
overall five-year survival rate of less than twenty percent. For patients with unresectable …
overall five-year survival rate of less than twenty percent. For patients with unresectable …
[引用][C] Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons
MS Makary, S Ramsell, E Miller, EW Beal… - World Journal of …, 2021 - wjgnet.com
Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons Home English
English 简体中文 Sign In BPG Management System F6Publishing-Submit a Manuscript …
English 简体中文 Sign In BPG Management System F6Publishing-Submit a Manuscript …